The Effect of Continuous, Various Doses of Furosemide Drip on Hearing as Measured by Acoustic Emission
Information source: Rabin Medical Center
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hearing Status
Phase: N/A
Status: Not yet recruiting
Sponsored by: Rabin Medical Center Official(s) and/or principal investigator(s):
Elhanan Nahum, MD, Study Director, Affiliation: Schneider Children's Hospital
Overall contact:
Elhanan - Nahum, MD, Phone: 972 3 9253686, Ext: -, Email: enahum@clalit.org.il
Summary
Pediatric patients, during their illness often treated with furosemide (Lasix) continuous
drip, often, with dosages above 4-6mg/kg/day (the recommended dose).
This study will monitor hearing status of these children prior to their therapy with
furosemide, during this therapy and after.
Clinical Details
Official title: The Effect of Continuous, Various Dosages of Furosemide Drip on Hearing as Measured by Acoustic Emission
Study design: Cohort, Prospective
Detailed description:
This study will record hearing status, by acoustic emission, of critically ill children,
treated with different dosages of furosemide drip.
Acoustic emission test will be done prior to therapy and q48 hours during their course of
treatment with furosemide drip.
Dosage of furosemide drip, boluses and other relevant medications (i. e - vancomycin,
muscular relaxants, aminoglycosides etc) will be recorded.
Eligibility
Minimum age: 1 Month.
Maximum age: 18 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- All children admitted to Pediatric ICU who are treated with furosemide continuous
drip.
Exclusion Criteria:
- Children with known hearing abnormalities prior to treatment.
Locations and Contacts
Elhanan - Nahum, MD, Phone: 972 3 9253686, Ext: -, Email: enahum@clalit.org.il
Pediatric ICU, Schneider Children's Hospital, Petah Tikva 49202, Israel
Additional Information
Starting date: August 2009
Ending date: August 2010
Last updated: July 23, 2009
|
